Amplified Benefit of Clopidogrel Versus Aspirin in Patients With Diabetes Mellitus


Phase N/A Results

Trial Description

To determine whether clopidogrel compared with aspirin would be particularly efficacious in preventing ischemic events in diabetic patients with atherosclerosis.


  • Aspirin (stroke prevention) Drug
    Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
  • Clopidogrel (Plavix®)Drug
    Other Names: Plavix, Clodelib, Clovelen
    Intervention Desc: Antiplatelet agent

Trial Design

Randomized, double-blinded, controlled clinical trial.

Patient Involvement

All patients were randomized to either clopidogrel (1,914) or aspirin (1,952) treatment groups. All analyses were performed on an on-treatment basis, with each patient’s time at risk censored 28 days after early discontinuation of the study drug.


Type Measure Time Frame Safety Issue
Primary Vascular death, all-cause stroke, MI, or rehospitalization for ischemia or bleeding.